The industry’s first ALK degrader starts its first human study.
ApexOnco Front Page
Recent articles
MK-6837, just like saci-T, is a TROP2-directed ADC, it has emerged.
ELVN-001 is made to look more like Terns’ TERN-701.
A pivotal trial will test the KRAS G12D degrader setidegrasib plus chemo in first-line PDAC.
The group’s on/off KRAS G12C inhibitor looks good, though patient numbers are small.
But Tevimbra’s role looks shaky as adverse events loom.
Four months after yielding first-in-human data INCA33890 enters phase 3.
JP Morgan approaches.
